Clinical Trial Update: Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery [Phase 1, Phase 2]

View source ↗

Summary

This update covers a Phase 1/2 trial of olaparib plus ramucirumab in patients with metastatic or locally recurrent gastric or gastroesophageal junction cancer t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Cyramza (ramucirumab)
• Lynparza (olaparib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Esophageal Carcinoma, Metastatic Gastric Carcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-06-04